SCHEMBL1773907

SCHEMBL1773907

C[C@H]1COCc2nc3c(N)nc4cc(C=CC(=O)N5CCOCC5)ccc4c3n21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.43
RAB9A P51151 8/20 0.42
NPC1 O15118 7/20 0.42
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAOB P27338 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
ICAM1 P05362 5/20 0.39
ITGB2 P05107 4/20 0.39
ITGAL P20701 4/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
GPR183 P32249 1/20 0.37
SELE P16581 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1773905 1.00 TRPV1 (0.43) TRPV1RAB9ANPC1TDP1ALDH1A1
SCHEMBL1774266 0.85 TLR7 (0.38) TLR8TLR7
SCHEMBL1774269 0.85 TLR7 (0.38) TLR8TLR7
SCHEMBL1774529 0.80 FKBP1A (0.40) RAB9ANPC1ALDH1A1HPGDKDM4E
SCHEMBL1775932 0.77 TLR7 (0.41) ALDH1A1HPGDTLR8TLR7
SCHEMBL1775391 0.75 TLR7 (0.41) TLR8TLR7
SCHEMBL4531584 0.75 TLR7 (0.51) TRPV1RAB9ANPC1TDP1ALDH1A1
SCHEMBL4531580 0.75 TLR7 (0.51) TRPV1RAB9ANPC1TDP1ALDH1A1
SCHEMBL1774551 0.74 FKBP1A (0.45) RAB9ANPC1ALDH1A1HPGDKDM4E
SCHEMBL10237186 0.73 TLR7 (0.44) POLBTLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546383-B2 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-10-01 US disclosed
US-20120232057-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY 2012-09-13 US disclosed
EP-1831226-B1 CHIRAL TETRACYCLIC COMPOUNDS INDUCING INTERFERON BIOSYNTHESIS 3M INNOVATIVE PROPERTIES CO (US) 2012-08-08 EP disclosed
US-8207162-B2 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-06-26 US disclosed
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY 2011-08-25 US disclosed
US-7943609-B2 Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides 3M INNOVATIVE PROPRERTIES COMPANY (US) 2011-05-17 US disclosed
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds IFNAR1, IFNG, IL4 TRPV1 3293/4885RAB9A 1298/4885NPC1 1586/4885
US-20120232057-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNAR1, IFNG, IL4 TRPV1 3320/4885RAB9A 1331/4885NPC1 1558/4885
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNAR1, IFNG, IL4 TRPV1 3293/4885RAB9A 1298/4885NPC1 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.